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 Oxaliplatin reacts with DMSO only in the presence of water 
 Oxaliplatin is stable in pure water and in pure DMSO, but reacts 
rapidly with DMSO in aqueous solution forming platinum species 
with one DMSO and one monodentate oxalate or 
hydroxide ligand. 
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Oxaliplatin reacts with DMSO only in the presence
of water†
Hristo P. Varbanov, *a,b Daniel Ortiz,a Doris Höfer,b Laure Menin,a
Markus Galanski,b Bernhard K. Kepplerb and Paul J. Dyson*a
Herein we show that oxaliplatin reacts rapidly with DMSO in
aqueous solutions, despite being stable in pure DMSO and pure
water. Furthermore, the reactivity of the clinically applied Pt(II)
drugs in water/DMSO and PBS/DMSO mixtures, and the nature of
the species formed were investigated by MS, NMR and RP-HPLC
techniques.
Cisplatin ([Pt(NH3)2Cl2]), carboplatin ([Pt(NH3)2(CBDCA)],
where CBDCA = 1,1-cyclobutanedicarboxylate), and oxaliplatin
([Pt(DACH)(Ox)], where DACH = (1R,2R)-1,2-diaminocyclo-
hexane and Ox = oxalate), are amongst the most eﬀective and
widely used anticancer drugs.1,2 They continue to be investi-
gated in numerous preclinical and clinical studies in diﬀerent
combinations with other non-platinum drugs,3–5 and are
widely used as benchmarks against which new putative metal-
based compounds are compared.
These above-mentioned studies are usually conducted in
aqueous media, often in the presence of dimethylsulfoxide
(DMSO), which is probably the most commonly employed
organic solvent in drug research and biological chemistry, due
to its ability to dissolve/solubilize a large variety of therapeuti-
cally active molecules, its low toxicity and good miscibility
with water.6–8 DMSO is also frequently used in experimental
(laboratory and drug screening) settings involving Pt drugs,9
despite its known reactivity with cisplatin and subsequent
eﬀects on cell viability.10–13 Hall et al. reiterated this problem
in a recent Cancer Research article entitled, “Say No to DMSO:
Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and
Other Platinum Complexes”.9 Therein, the authors examined
the eﬀects of DMSO on the in vitro biological activity of the
clinically approved Pt-drugs, as well as of some relevant experi-
mental complexes. A significant decrease in the cytotoxicity of
cisplatin and related dichloridoplatinum(II) complexes in
several cancer cell lines was observed when their stock solu-
tions were prepared in DMSO compared to the respective clini-
cal formulations. Such findings are corroborated by the known
lability of monodentate leaving groups such as chloride and
the aﬃnity of Pt(II) to nucleophilic sulphur donors.14–16
Dicarboxylatoplatinum(II) complexes such as carboplatin and
oxaliplatin possess lower reactivity, respectively rate of
exchange of the bidentate ligand compared to cisplatin17–19
and therefore a smaller eﬀect of DMSO on their anticancer
activity could be expected. Accordingly, Yi and Bae showed
that cisplatin completely loses its activity against A2780 cells
after 8 days of storage in DMSO (at 4 °C), while the potency of
carboplatin and oxaliplatin is only slightly aﬀected under the
same conditions.20 Nevertheless, Hall et al. reported a 3- to
10-fold decrease of the cytotoxic activity of carboplatin when
dissolved in DMSO whereas, intriguingly, no eﬀect or only a
slight potentiating eﬀect of DMSO on the cytotoxicity of oxali-
platin was found. Furthermore, the authors confirmed (by
means of ESI MS) the formation of Pt-DMSO species in DMSO
solutions of cisplatin and carboplatin, but not for oxaliplatin.9
Using ESI MS, we noticed that oxaliplatin is stable in pure
DMSO, but reacts rapidly with DMSO in aqueous solutions,
prompting us to further investigate the reactivity of oxaliplatin
(in comparison with cisplatin and carboplatin) in DMSO/water
mixtures. The stability of cisplatin, carboplatin and oxaliplatin
in DMSO-d6 was monitored over 48 h at RT using
1H NMR
spectroscopy. As expected, cisplatin undergoes fast solvolysis
(Fig. S1a,d†), whereas only minor changes were observed for car-
boplatin and oxaliplatin over 48 h of incubation (Fig. S1b,c†).
These diﬀerences, i.e. a fast reaction between cisplatin and
DMSO (Fig. S2†) and the high stability of carboplatin and
oxaliplatin under the same conditions, were confirmed also by
ESI MS. After 30 h in DMSO, only trace amounts (relative inten-
sity of <1%) corresponding to Pt-DMSO adducts (i.e. [Pt(NH3)
(DMSO)(CBDCA) + Na]+ and [Pt(NH3)2(CBDCA)(DMSO) + Na]
+
for carboplatin; [Pt(DACH)(Ox)(DMSO) + H]+ for oxaliplatin)
were identified. In contrast, MS signals characteristic for oxali-
platin rapidly diminish in aqueous solutions containing
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c7dt01628j
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1–10% DMSO with the growth of new peaks corresponding to
DACH-Pt species, featuring one DMSO and one monodentate
oxalate or hydroxide ligand (see Table 1, Scheme 1 and
Fig. S3†).
The reaction between oxaliplatin, DMSO and water was
further studied by dissolving oxaliplatin (1 mM) in anhydrous
DMSO and diluting the solution with water (1 : 20). The
dilution was rapidly injected into the MS (for further details
check the Experimental section in the ESI†). The evolution of
the peaks corresponding to Pt-DMSO adducts formed (Table 1)
versus the peaks corresponding to intact oxaliplatin was
recorded in real time over 30 min. As shown in Fig. 1, the rela-
tive intensity of the signals corresponding to native oxaliplatin
([Pt(DACH)(Ox) + (H/Na/K)]+ at m/z 398.0674 (+H+), 420.0493
(+Na+) and 436.0233 (+K+)) drops rapidly to 33.5% in
29 minutes whereas the intensity of the peak attributed to
[Pt(DACH)(OH)(DMSO)]+ increases to 63.2% in the same
period. The diﬀerent species of the type [Pt(DACH)(Ox)(DMSO) +
(H/Na/K)]+ are formed faster (7.2% at 0.8 minutes), but remain
below 9% during the entire experiment.
Next, we studied the respective clinical formulations of the
Pt drugs (i.e. cisplatin – 3.3 mM in 0.9% saline; carboplatin –
27 mM in 5% glucose solution and oxaliplatin – 12.6 mM in
5% glucose solution) and diluted them with PBS (pH = 7.4)/
DMSO or water/DMSO mixtures with diﬀerent concentrations
of DMSO (0–10%) to give a final concentration of the com-
plexes of 1 mM. The formation of DMSO adducts at RT was fol-
lowed by recording ESI MS (after the respective dilutions with
the water/MeOH (10 : 1) mixture) at diﬀerent time points for a
period of 2 h (for cisplatin) and 40 h (for carboplatin and oxa-
liplatin). Cisplatin reacted with DMSO comparatively quickly
in pure DMSO and in a mixture with water (Fig. S2†). In the
case of carboplatin and oxaliplatin (both stable in pure DMSO
and pure water) the rate of formation of DMSO adducts was
dependent on the amount of DMSO in the solvent mixture, as
shown in Fig. 2 for oxaliplatin. Oxaliplatin reacts almost com-
pletely to form mono-DMSO adducts within few hours in
water/DMSO (10 : 1). DMSO coordinates to the Pt center, which
causes the opening of the oxalato ring. The monodentately
bound oxalate is further cleaved and exchanged with OH in
H2O/DMSO or Cl in PBS/DMSO mixtures (Scheme 1, Fig. S3–
S5†), and the reaction is considerably faster in PBS/DMSO (see
Fig. 2, S4 and S6†). The rate enhancement in PBS/DMSO (com-
pared to H2O/DMSO) may be caused by the coordination of Cl
to the Pt center21,22 before or after DMSO coordination and/or
the eﬀect of phosphate and pH.
Scheme 1 Formation of Pt-DMSO adducts in DMSO/H2O and DMSO/
PBS (pH = 7.4) solutions of oxaliplatin.
Fig. 1 Relative intensity of the peaks corresponding to intact oxaliplatin
([Pt(DACH)(Ox) + (H/Na/K)]+, red ), [Pt(DACH)(OH)(DMSO)]+ (black ■)
and [Pt(DACH)(Ox)(DMSO) + (H/Na/K)]+ (blue ) as a function of time in
the ESI MS from a solution of oxaliplatin in DMSO after dilution with
water (1 : 20). See Table 1 for details of peak assignments.
Table 1 Pt-DMSO adducts identiﬁed in the ESI+ mass spectra of carboplatin and oxaliplatin after 24 h of incubation in DMSO/water (1 : 10)
Molecular species Formula Observed massa Theoretical mass Error (ppm)
Carboplatin
[Pt(NH3)2(CBDCA)(DMSO) + H]
+ C8H19N2O5PtS 450.0664 450.0657 1.5
[Pt(NH3)2(CBDCA)(DMSO) + Na]
+ C8H18N2O5PtSNa 472.0483 472.0476 1.5
[Pt(NH3)(DMSO)(CBDCA) + H]
+ C8H16NO5PtS 433.0393 433.0391 0.5
[Pt(NH3)(DMSO)(CBDCA) + Na]
+ C8H15NO5PtSNa 455.0218 455.0211 1.1
[Pt2(NH3)3(DMSO)(CBDCA)2 + H]
+ C14H28N3O9Pt2S 804.0851 804.0836 1.8
[Pt2(NH3)3(DMSO)(CBDCA)2 + Na]
+ C14H27N3O9Pt2SNa 826.0672 826.0656 1.9
Oxaliplatin
[Pt(DACH)(OH)(DMSO)]+ C8H21N2O2PtS 404.0972 404.0966 1.4
[Pt(DACH)(Ox)(DMSO) + H]+ C10H21N2O5PtS 476.0817 476.0813 0.9
[Pt(DACH)(Ox)(DMSO) + Na]+ C10H20N2O5PtSNa 498.0635 498.0633 0.6
[Pt(DACH)(Ox)(DMSO) + K]+ C10H20N2O5PtSK 514.0373 514.0372 0.5
aObserved/theoretical masses are given for the monoisotopic peaks.
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Carboplatin reacts with DMSO in water/DMSO mixtures,
albeit at a much slower rate than oxaliplatin. After 48 h of
incubation in water/DMSO (10 : 1), approximately 50% of car-
boplatin reacted to form adducts with DMSO, while in the
(100 : 1) mixture the conversion was <20% (Fig. S7†). ESI MS
spectra revealed the formation of several species, with the
peak corresponding to [Pt(NH3)(DMSO)(CBDCA)] (also
reported by Hall et al.9) being the most abundant. Peaks
corresponding to adducts where DMSO causes the opening of
the CBDCA ring (e.g., [Pt(NH3)2(CBDCA)(DMSO) + H]
+), as well
as dimeric species, were also detected (see Tables 1 and S1
and Fig. S8†). The existence of at least three (incl. parent car-
boplatin) species in solution after 40 h of incubation was also
confirmed by 13C and 195Pt NMR spectroscopy and RP-HPLC
(Fig. S9†). All species detected during the time-dependent ESI
MS experiments with cisplatin, carboplatin and oxaliplatin are
listed in Table S1.†
To further verify and also gain deeper insight into the reac-
tion between oxaliplatin and DMSO in DMSO/water mixtures,
time-dependent 13C NMR spectroscopic studies using oxalipla-
tin with a 13C2-labeled oxalato ligand were performed. The
reaction could be easily monitored following the changes in
the 160–180 ppm region, where resonance(s) attributable to
the oxalate carbon atoms are found. The signal characteristic
for parent oxaliplatin decreases with time, and four signals
belonging to monodentate 13C2-labeled oxalate (
1JC,C = 82.5
Hz) increase; a sixth signal corresponding to free oxalate was
also observed in most cases (Fig. 3). The 13C NMR data corro-
borates with oxaliplatin-DMSO adducts observed in the ESI MS
experiments. However, according to NMR spectra, the for-
mation of the DMSO adduct with monodentate oxalate
appears to dominate over the complete release of oxalate and
the formation of [Pt(DACH)(OH)(DMSO)]+ (Fig. S10†). These
observations were substantiated by RP-HPLC-MS experiments
(Fig. S5†). The observed diﬀerence between ESI MS and NMR/
LC-MS data may be attributed to the easier detection of the
naturally charged [Pt(DACH)(OH)(DMSO)]+ complex compared
to the neutral [Pt(DACH)(Ox)(DMSO)] species, reflected in the
higher abundance in the positive ion ESI mass spectra of the
former complex.
The addition of NaCl (5 eq.) led to rapid substitution of the
monodentate oxalate and the formation of [Pt(DACH)Cl
(DMSO)]+, as evidenced from 13C and 195Pt NMR spectroscopy
(Fig. S11†) and ESI MS. Monitoring the reaction of oxaliplatin
in DMSO/water mixtures (0.1, 1, 10, 50 and 90% DMSO) shows
that the reaction rate increases with increasing concentrations
of DMSO, reaching a maximum rate and then decreasing
(Fig. 4). The reaction is slow (t1/2 > 3 days) and incomplete
when the amount of water is ≤10%, and is fast (t1/2 = 3–5 h)
when the amount of DMSO is between 10 and 50%.
The ESI MS and NMR spectroscopic studies described
above (see also the scheme in Fig. S12†) show that oxaliplatin
does not react with pure DMSO and no evidence was found for
Pt-oxalate ring opening. Oxaliplain is also stable in pure water
(despite reacting with it) as the reverse ring closure reaction is
extremely fast.23,24 In DMSO/water mixtures, however, DMSO
appears to eﬀectively arrest the ring closure reaction, rapidly
Fig. 2 (a) Change in the relative intensity of the MS peaks corres-
ponding to intact oxaliplatin as a function of time in a clinical formu-
lation of oxaliplatin (12.6 mM in 5% glucose solution), diluted with
diﬀerent water/DMSO and PBS/DMSO mixtures as determined by ESI
MS. (b) Time-dependent change in the relative intensity of peaks corres-
ponding to the species formed in a clinical formulation of oxaliplatin
after dilution with water/DMSO (10 : 1) as observed in the ESI MS+
spectra.
Fig. 3 13C NMR spectra of oxaliplatin analogue with 13C2-labeled
oxalate in a D2O/DMSO-d6 (10 : 1) mixture as a function of time at RT (a,
chelating oxalate ligand; b, monodentate oxalate; c, uncoordinated
oxalate).
Fig. 4 Rate of reaction of the oxaliplatin analogue featuring
13C2-labeled oxalate and DMSO in diﬀerent water/DMSO mixtures
determined by 13C NMR spectroscopy.
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coordinating with the ring-opened monoaquated oxaliplatin
adduct to form [Pt(DACH)(Ox)(DMSO)]. Notably, only species
with one coordinated DMSO were detected, presumably due to
the mutual labilization of two cis-coordinated DMSO
ligands.25,26 In DMSO/water solutions [Pt(DACH)(Ox)(DMSO)] is
in equilibrium with [Pt(DACH)(OH)(DMSO)]+, while the amount
of the former species prevails. However, in the presence of
chloride [Pt(DACH)Cl(DMSO)]+ rapidly forms (Fig S12†).
Carboplatin is also stable in pure DMSO and pure water,
but reacts with DMSO in DMSO/water mixtures, nevertheless
at a slower rate than oxaliplatin, in accordance with its slower
rate of aquation/ring-opening,23 due to the higher stability of
the six-membered Pt-CBDCA ring, compared to the five-mem-
bered Pt-oxalate ring in oxaliplatin. Moreover, the substitution
of an ammine ligand by DMSO in carboplatin is favored over
the formation of complex with one DMSO and a monodentate
CBDCA ligand.
Previous studies reported ring opening of carboplatin, oxali-
platin and related complexes by biologically relevant nucleo-
philes, e.g. 5′-GMP, L-Met, thiourea, GSH, etc., claiming that
the major reaction path involves direct nucleophile attack on
the intact (non-aquated) platinum complex.27–29 However,
these studies were performed in aqueous media and, based on
the results reported here, the prior formation of monoaquated
platinum species cannot be excluded.
In summary, our studies show that carboplatin and oxali-
platin are stable in DMSO in contrast to cisplatin and other
dichloridoplatinum(II) complexes. Nevertheless, DMSO should
be avoided in any biological experiments involving carboplatin
and oxaliplatin as the aqueous media mediate the formation
of DMSO adducts, which are not representative of the clinically
used formulations, and is likely to lead to results diﬀerent
from those obtained in the absence of DMSO. In this context,
the slightly potentiating eﬀect of DMSO on the cytotoxicity of
oxaliplatin observed by Hall et al.9 may be attributed to the
formation of [Pt(DACH)(DMSO)Cl]Cl, a species for which anti-
tumor activity has been reported.25
H. V. is indebted to the Austrian Science Fund (FWF) for
the financial support (Schrödinger fellowship, Project number:
J3577-B13).
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